Biological Trace Element Research

, Volume 187, Issue 1, pp 192–201 | Cite as

Trivalent Chromium Supplementation Ameliorates Oleic Acid-Induced Hepatic Steatosis in Mice

  • Song Wang
  • Jian Wang
  • Yajing Liu
  • Hui Li
  • Qiao Wang
  • Zhiwei Huang
  • Wenbin Liu
  • Ping Shi


Trivalent chromium [Cr(III)] is recognized as an essential trace element for human health, whereas its effect on hepatic lipid metabolism has not yet been fully understood. This study aimed to investigate the beneficial effects and potential mechanisms of Cr(III) on hepatic steatosis in an oleic acid (OA) induced mice model. Mice were fed with high OA for 12 weeks to induce lipid accumulation, and co-administrated with Cr(III) supplementation. Indexes of liver lipid accumulation, associated lipid genes expression, fatty acids (FAs) profile and inflammatory cytokines were analyzed. The data showed that Cr(III) supplementation could attenuate disease progress of hepatic steatosis and protect liver from high OA. After Cr(III) supplementation, elevated body weight and liver injury in steatosis mice were reversed, excessive lipid accumulation and FAs were also reduced. The up-regulation of cluster of differentiation 36 (CD36) and diacylglycerol acyltransferase 2 (DGAT2) following steatosis induction were inhibited by Cr(III). Cr(III) reduced the content of pro-inflammatory cytokines (IL-1β and TNF-α, IL-12) and restored the level of anti-inflammatory cytokine (IL-10) to the control values. Our results suggest that Cr(III) supplementation is a novel strategy for alleviating OA-induced hepatic steatosis.


Steatosis Trivalent chromium CD36 DGAT2 Inflammatory cytokines 



This work was sponsored by grants from National Natural Science Foundation of China (31671309), and the Opening Project of Shanghai Key Laboratory of Crime Scene Evidence (2016XCWZK13).

Compliance with Ethical Standards

Conflicts of Interest

The authors confirm that this article content has no conflict of interests.


  1. 1.
    Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346(16):1221–1231. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ (2003) Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 39(6):978–983CrossRefGoogle Scholar
  3. 3.
    Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37(2):343–350. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pan MH, Lai CS, Ho CT (2010) Anti-inflammatory activity of natural dietary flavonoids. Food Funct 1(1):15–31. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pechova A, Pavlata L (2007) Chromium as an essential nutrient: a review. Veterinarni Medicina 52(1):1–18CrossRefGoogle Scholar
  6. 6.
    Roussel AM, Andriollo-Sanchez M, Ferry M, Bryden NA, Anderson RA (2007) Food chromium content, dietary chromium intake and related biological variables in French free-living elderly. Br J Nutr 98(2):326–331. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mahdi GS (1996) Chromium deficiency might contribute to insulin resistance, type 2 diabetes mellitus, dyslipidaemia, and atherosclerosis. Diabet Med 13(4):389–390.<389::AID-DIA65>3.0.CO;2-J CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Abraham AS, Brooks BA, Eylath U (1992) The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 41(7):768–771CrossRefGoogle Scholar
  9. 9.
    Shafik NM, Baalash A, Ebeid AM (2017) Synergistic Cardioprotective effects of combined chromium Picolinate and atorvastatin treatment in triton X-100-induced hyperlipidemia in rats: impact on some biochemical markers. Biol Trace Elem Res 180(2):255–264. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37(8):911–917. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang ZQ, Qin J, Martin J, Zhang XH, Sereda O, Anderson RA, Pinsonat P, Cefalu WT (2007) Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism 56(12):1652–1655. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sadri H, Larki NN, Kolahian S (2017) Hypoglycemic and Hypolipidemic effects of leucine, zinc, and chromium, alone and in combination, in rats with type 2 diabetes. Biol Trace Elem Res 180(2):246–254. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mertz W (1993) Chromium in human nutrition: a review. J Nutr 123(4):626–633CrossRefGoogle Scholar
  14. 14.
    Chen WY, Chen CJ, Liao JW, Mao FC (2009) Chromium attenuates hepatic damage in a rat model of chronic cholestasis. Life Sci 84(17–18):606–614CrossRefGoogle Scholar
  15. 15.
    Wang S, Wang J, Zhang X, Hu L, Fang Z, Huang Z, Shi P (2016) Trivalent chromium alleviates oleic acid induced steatosis in SMMC-7721 cells by decreasing fatty acid uptake and triglyceride synthesis. Biometals 29(5):881–892. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J (2004) Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106(6):635–643. CrossRefGoogle Scholar
  17. 17.
    Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290(5):G852–G858. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ruiz-Gutiérrez V, Pérez-Espinosa A, Vázquez CM, Santa-María C (1999) Effects of dietary fats (fish, olive and high-oleic-acid sunflower oils) on lipid composition and antioxidant enzymes in rat liver. Br J Nutr 82:233–241PubMedPubMedCentralGoogle Scholar
  19. 19.
    Ducheix S, Montagner A, Polizzi A, Lasserre F, Régnier M, Marmugi A, Benhamed F, Bertrand-Michel J, Mselli-Lakhal L, Loiseau N, Martin PG, Lobaccaro JM, Ferrier L, Postic C, Guillou H (2017) Dietary oleic acid regulates hepatic lipogenesis through a liver X receptordependent signaling. PLoS One 12.
  20. 20.
    Chen WY, Chen CJ, Liu CH, Mao FC (2010) Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice. Biochem Biophys Res Commun 397:459–464. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497–509PubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang S, Kuang X, Fang Z, Huang Z, Shi P (2014) Effect of oleic acid on the levels of eight metal ions in human hepatoma SMMC-7721 cells. Biol Trace Elem Res 159(1–3):445–450. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schwarz K, Mertz W (1959) Chromium(III) and the glucose tolerance factor. Arch Biochem Biophys 85:292–295CrossRefGoogle Scholar
  24. 24.
    Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39(1):179–187. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jensen-Urstad AP, Semenkovich CF (2012) Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? Biochim Biophys Acta 1821(5):747–753. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wakil SJ, Abu-Elheiga LA (2009) Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 50(Suppl):S138–S143. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ibrahimi A, Abumrad NA (2002) Role of CD36 in membrane transport of long-chain fatty acids. Curr Opin Clin Nutr Metab Care 5(2):139–145CrossRefGoogle Scholar
  28. 28.
    Iqbal J, Hussain MM (2009) Intestinal lipid absorption. Am J Physiol Endocrinol Metab 296(6):E1183–E1194. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR (2007) Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56(12):2863–2871. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Buque X, Martinez MJ, Cano A, Miquilena-Colina ME, Garcia-Monzon C, Aspichueta P, Ochoa B (2010) A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res 51(3):500–513. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T, Vargas-Castrillon J, Buque X, Ochoa B, Aspichueta P, Gonzalez-Gallego J, Garcia-Monzon C (2011) Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 60(10):1394–1402. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Yen C-LE, Stone SJ, Koliwad S, Harris C, Farese RV (2008) Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 49(11):2283–2301CrossRefGoogle Scholar
  33. 33.
    Mo X, Yang C, Wang X, Burkhardt BR, Li Y, Xia H, Cao X (2015) F3MB(PANDER) decreases mice hepatic triglyceride and is associated with decreased DGAT1 expression. PLoS One 10(2):e0117156. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zhao Y, Pan Y, Yang Y, Batey R, Wang J, Li Y (2015) Treatment of rats with Jiangzhi capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2. J Transl Med 13:174. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, Farese RV (2004) Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 279(12):11767–11776CrossRefGoogle Scholar
  36. 36.
    Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI (2007) Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 282(31):22678–22688. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Choi YJ, Lee CH, Lee KY, Jung SH, Lee BH (2015) Increased hepatic fatty acid uptake and esterification contribute to tetracycline-induced steatosis in mice. Toxicol Sci 145(2):273–282. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Clugston RD, Yuen JJ, Hu Y, Abumrad NA, Berk PD, Goldberg IJ, Blaner WS, Huang LS (2014) CD36-deficient mice are resistant to alcohol- and high-carbohydrate-induced hepatic steatosis. J Lipid Res 55(2):239–246. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sato T, Morita A, Mori N, Miura S (2014) The role of glycerol-3-phosphate dehydrogenase 1 in the progression of fatty liver after acute ethanol administration in mice. Biochem Biophys Res Commun 444(4):525–530. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P (2009) Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24:830–840. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482(7384):179–185. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M (2014) Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 20(48):18070–18091. CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, Lafdil F, Gao B (2011) Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 54(3):846–856. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.State Key Laboratory of Bioreactor EngineeringEast China University of Science and TechnologyShanghaiChina
  2. 2.Shanghai Key Laboratory of Crime Scene EvidenceShanghai Research Institute of Criminal Science and TechnologyShanghaiChina
  3. 3.College of Chemistry, Chemical Engineering and BiotechnologyDonghua UniversityShanghaiChina

Personalised recommendations